ArticleBMC microbiology2025
Current drug susceptibility testing in the Löwenstein-Jensen medium leads to underestimating of prothionamide resistance in multi-drug resistant Mycobacterium tuberculosis.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeThis study aimed to resolve inconsistencies in prothionamide (PTO) drug susceptibility testing (DST) results between solid and liquid media by validating the appropriate critical concentrations for PTO DST in solid media. It also aimed to assess the correlation between phenotypic resistance and genetic mutations in ethA and the inhA promoter.
methodsA total of 100 multidrug-resistant tuberculosis (MDR-TB) isolates were tested for PTO susceptibility using the MGIT 960 system, Löwenstein-Jensen (L-J) medium, and Middlebrook 7H10 medium with varying PTO concentrations. Genotypic resistance was determined by PCR and sequencing of ethA and the inhA promoter.
resultsWhen MGIT 960 was used as the reference, 20 mg/L for L-J and 10 mg/L for 7H10 achieved the highest agreement (kappa = 0.865 and 0.827, respectively). Using Sanger sequencing as the reference, the highest kappa (0.594) was observed for MGIT 960 when defining resistance as inhA c-15t and/or loss-of-function mutations in ethA. At 20 mg/L, L-J medium provided a balanced sensitivity (71.4%) and specificity (84.6%), whereas 40 mg/L increased specificity but markedly reduced sensitivity. Six isolates showed suboptimal growth on 7H10, suggesting it may not support robust culture of MDR strains. Wild-type inhA and ethA profiles demonstrated high negative predictive value (NPV 90.2–100.0%), reliably excluding resistance.
conclusionsA critical concentration of 40 mg/L for PTO in L-J medium may underestimate resistance. A lower concentration of 20 mg/L offers improved detection but requires genotypic confirmation owing to lower PPV. The 7H10 medium may not be optimal for MDR-TB DST due to limited growth support. Integrating phenotypic and molecular methods is recommended for accurate resistance detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.